1. Combining Abiraterone and Radiotherapy in Prostate Cancer Patients Who Progressed During Abiraterone Therapy
- Author
-
Luca Eolo Trodella, Tommaso Carfagno, Alessio Bruni, Riccardo Santoni, Simona Borghesi, Lorenzo Livi, Gianluca Ingrosso, Rolando Maria D'Angelillo, Luca Triggiani, S. Fondelli, Roberto Santini, Emanuela Olmetto, Giulio Francolini, and Beatrice Detti
- Subjects
Male ,0301 basic medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,Abiraterone ,CRPC ,radiotherapy ,treatment duration ,Aged ,Aged, 80 and over ,Androstenes ,Combined Modality Therapy ,Cytochrome P-450 Enzyme Inhibitors ,Humans ,Middle Aged ,Prostatic Neoplasms, Castration-Resistant ,Survival Analysis ,medicine.medical_treatment ,Treatment outcome ,Castration-Resistant ,Settore MED/06 ,03 medical and health sciences ,Prostate cancer ,chemistry.chemical_compound ,0302 clinical medicine ,Settore MED/36 ,Internal medicine ,80 and over ,Medicine ,Survival analysis ,business.industry ,Abiraterone acetate ,Prostatic Neoplasms ,General Medicine ,medicine.disease ,Surgery ,Radiation therapy ,030104 developmental biology ,chemistry ,Radiotherapy ,Treatment duration ,030220 oncology & carcinogenesis ,Palliative intent ,business - Abstract
Background/aim This multicenter, retrospective, 'field-practice' study investigated treatment outcomes of ongoing abiraterone therapy with the addition of radiotherapy (RT) - initiated for oligoprogression or with a palliative intent. Patients and methods Consecutive patients affected by metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate were considered if they had received RT after the initiation of abiraterone treatment. Results A total of 32 patients were enrolled in the study. Median duration of abiraterone treatment was 13.0 months (range=3.8-40.9 months). Median duration of abiraterone treatment before RT was 5.9 months (range=0.4-40.0 months), and 7.2 months after RT (range=0.1-29.7 months). Median progression-free survival (PFS) was 12.6 months (95%CI=10.5-14.7) from the initiation of abiraterone treatment. From RT administration, PFS was 9.6 months (95%CI=6.4-12.9). Median overall survival (OS) since abiraterone initiation was 18.9 months (95%CI=4.7-33.0). Conclusion RT prolongs abiraterone treatment in mCRPC patients leading to better clinical outcomes with this molecule.
- Published
- 2017
- Full Text
- View/download PDF